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Introduction 
According to the World Health Organization (WHO), an esti-
mated number of 31% of all deaths in 2012 were attributed to car-
diovascular diseases (CVDs) [1]. As an entity of CVD, myocardial 
infarction (MI) causes the death of millions of cardiomyocytes, and 
further triggers a remodeling process that can finally lead to 
chronic heart failure (HF). Unfortunately, current therapeutic 
strategies are only able to delay the progress of the disease but not 
to stop or to reverse it [2]. In particular, the socio-economic bur-
den created by the increasing number of incurable ischemic heart 
disease accentuates the substantial need for the development of 
new curative approaches for cardiac repair [2, 3].
Regenerative medicine is a rapidly emerging field aiming to 
repair the diseased tissue. Stem cell therapy has been proposed 
as a novel approach for the treatment of HF, either in the acute 
state after MI or in the chronic setting. The concept of stem cell 
delivery to the heart via different routes has been proven feasible 
and safe in several preclinical and clinical trials. Moreover, there 
is evidence that stem cell-based therapies are capable of moder-
ately improving cardiac function in diseased hearts. However, 
clinical outcomes regarding the efficiency of the therapies have 
been heterogeneous so far and could not fulfill the expectations 
[3]. Several parameters need to be considered and optimized for 
the development of an efficient cell therapy. These include the 
delivery route, the timing, the dose, and in particular the cell 
type [4].
An interesting cell source is the bone marrow as it contains dif-
ferent cell types, including bone marrow mononuclear cells 
(BMMNCs) and their subpopulations. The use of bone marrow-
derived cells is advantageous because these can be obtained in clin-
ically relevant numbers and they have been proven to be safe. 
BMMNCs as well as hematopoietic (HPCs) and endothelial pro-
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Summary
Cardiac stem cell therapy holds great potential to prompt 
myocardial regeneration in patients with ischemic heart 
disease. The selection of the most suitable cell type is piv-
otal for its successful application. Various cell types, in-
cluding crude bone marrow mononuclear cells, skeletal 
myoblast, and hematopoietic and endothelial progenitors, 
have already advanced into the clinical arena based on 
promising results from different experimental and preclin-
ical studies. However, most of these so-called first-gener-
ation cell types have failed to fully emulate the promising 
preclinical data in clinical trials, resulting in heterogene-
ous outcomes and a critical lack of translation. Therefore, 
different next-generation cell types are currently under 
investigation for the treatment of the diseased myocar-
dium. This review article provides an overview of current 
stem cell therapy concepts, including the application of 
cardiac stem (CSCs) and progenitor cells (CPCs) and line-
age commitment via guided cardiopoiesis from multipo-
tent cells such as mesenchymal stem cells (MSCs) or 
pluripotent cells such as embryonic and induced pluripo-
tent stem cells. Furthermore, it introduces new strategies 
combining complementary cell types, such as MSCs and 
CSCs/CPCs, which can yield synergistic effects to boost 
cardiac regeneration. © 2016 S. Karger GmbH, Freiburg
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genitor cells (EPCs) have been isolated and applied for cardiac re-
generation [5]. However, the outcomes in numerous clinical trials 
were heterogeneous [6]. Skeletal myoblasts (SMs) were one of the 
first cell types tested for cardiac regeneration in humans. Unfortu-
nately, their differentiation into myotubes was not accompanied by 
electrical coupling to resident cardiomyocytes and, importantly, a 
side effect of the SM transplantation was the occurrence of ven-
tricular arrhythmias [7]. Bone marrow-derived mesenchymal stem 
cells (BMMSCs) have also been suggested because of their favora-
ble safety profile, their immunoprivileged state, and their se-
cretome [8]. Indeed, there are several performed and ongoing pre-
clinical and clinical trials showing promising results in terms of 
safety [9, 10].
Despite the auspicious regenerative properties of mesenchymal 
stem cells (MSCs), the interest has shifted within the last few years 
towards cell types that can directly contribute to cardiac regenera-
tion, such as cardiac stem (CSCs) and progenitor cells (CPCs). 
While MSCs are supposed to aid in cardiac repair through para-
crine signaling and differentiation into different cell types, stem cell 
therapy with CSCs/CPCs aims to repair the diseased myocardium 
by matching the target organ and replacing the damaged and lost 
cardiomyocytes. The heart has limited regenerative capacities that 
can be enhanced by the addition of suitable cell types such as MSCs 
[11]. However, little is known on how far this regeneration can be 
pushed. Therefore, next-generation cell types, such as CSCs/CPCs 
and lineage-specified cells, raised the hope to improve regenerative 
strategies for heart repair.
This review article summarizes state-of-the-art cardiac stem cell 
therapy approaches. In particular, it gives an overview of CSCs/
CPCs and their performance in preclinical and clinical trials. 
Moreover, a focus will be on lineage-specified cells obtained via 
guided cardiopoiesis from different multipotent and pluripotent 
cell sources. Finally, the combination of cardiac cell types with 
complementary cell types, such as MSCs, will be highlighted as a 
potential strategy for the further enhancement of current therapies 
that involve a single cell type.
Cardiac Stem and Progenitor Cells
Stem cell therapy with CSCs/CPCs is relatively novel compared 
to cell therapies using more traditional cell types, such as MSCs 
and other bone marrow cell populations. The regenerative poten-
tial of the human heart has been discovered only recently and is 
still controverted. It has been shown by different groups and with 
different techniques that the human heart has a regeneration turn-
over of about 1% per year [12]. However, the origin of this regen-
eration and the related mechanisms are not fully understood yet. 
It is not clear whether human cardiomyocytes truly proliferate 
and/or dedifferentiate [12] and whether real stem cells, which are 
capable of self-renewal and differentiation, exist in the human 
heart. The presence of progenitor cells has been repeatedly sug-
gested. Nevertheless, their roles and mechanisms remain to be un-
covered. CSCs/CPCs can be isolated from heart biopsies that are 
performed during interventional surgical procedures. They are 
defined by their multipotency and clonogenicity as well as by the 
presence of common stem cell markers, such as c-kit and Sca-1, 
and cardiac markers, such as Isl-1, Nkx2.5 and GATA4 [13]. Cells 
that migrate from cultured cardiac explants can form cardio-
spheres, which can then be dissociated to obtain cardiosphere- 
derived cells (CDCs) [14]. 
The investigation of CSCs/CPCs is still at its infancy with only a 
limited number of in vivo studies and a few clinical trials. Several 
studies have been conducted in vitro to explore the mechanisms of 
cardiac regeneration. Remarkably, it has been shown that CPCs ex-
pressing Isl-1, Nkx2.5, and GATA4 are present in the postnatal 
mouse, rat, and human heart and that they differentiate into cardi-
omyocytes in vitro [15].
Preclinical trials have also been conducted with encouraging re-
sults in small and large animal models. Interestingly, the origin of 
the investigated CPCs includes both autologous and allogeneic 
cells. Cardiospheres and CDCs have been transplanted into pigs 
with promising results [16–19]. Allogeneic CDCs have been shown 
safe (no microvascular obstruction) and efficient (decrease in in-
farct size and adverse remodeling compared to controls) when de-
livered intracoronary at different doses (from 5 to 10 million cells) 
into pigs [17].
Several ongoing clinical trials are also demonstrating safety, fea-
sibility, and promising results concerning efficacy. The two most 
famous clinical trials are the Cardiac Stem Cell Infusion in Patients 
With Ischemic Cardiomyopathy trial (SCIPIO, NCT00474461) and 
the CArdiosphere-Derived aUtologous stem CElls to reverse ven-
tricUlar dysfunction trial (CADUCEUS, NCT00893360).
SCIPIO is a phase I, first-in-man, randomized study that inves-
tigates intracoronary transplantation of autologous c-kit+ CSCs 
into 33 patients (20 treated and 13 controls) with ischemic cardio-
myopathy. Significant increase in left ventricular ejection fraction 
(LVEF) and decrease in infarct size were shown 4 and 12 months 
after cell delivery. An improvement in LV function was shown by 
cardiac magnetic resonance imaging (cMRI) [20].
The CADUCEUS trial is also a phase I, randomized clinical trial 
that involved 17 patients (9 treated and 8 controls). It addresses the 
intracoronary administration of autologous CDCs at escalating 
doses of 12.5–25 million cells 1.5–3 months after acute myocardial 
infarction. At the 6-month follow-up, the cell therapy was shown 
to be safe (no cardiac tumors, major adverse cardiac events or 
death), with promising results regarding efficacy as measured by 
MRI (significant decrease in scar mass, increase in viable heart 
mass, and contractility compared to controls). These preliminary 
results were found to be consistent with cardiac regeneration 1 year 
after treatment [21].
Another clinical trial that addresses the use of CSCs for 
cardiac repair is the AutoLogous Human CArdiac-Derived Stem 
Cell to Treat Ischemic cArdiomyopathy trial (ALCADIA, 
NCT00981006). This phase I study was initiated in 2010 and 
aimed at assessing the safety and efficacy of autologous CSC 
 delivery with controlled release of basic fibroblast growth factor 
(bFGF) in HF patients. The treatment appeared to be safe and 
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showed decreased scar size together with increased LVEF 6 
months after implantation.
To date, only a few clinical trials investigate the use of allogeneic 
cardiac cells. These are the Allogeneic Heart Stem Cells to Achieve 
Myocardial Regeneration trial (ALLSTAR, NCT01458405) and the 
recent CAREMI trial (NCT02439398). The phase I/II ALLSTAR 
study was started in 2012, and patients are currently recruited. The 
goal is to evaluate the effect of allogeneic CDCs on scar size after 
acute MI. The CAREMI trial is a first-in-man, randomized phase I/
II study that aims to investigate the intracoronary injection of dif-
ferent doses of allogeneic CSCs. 
Cardiac repair through CSCs/CPCs therapies only begins to be 
explored. Although initial studies yielded promising results, these 
need to be confirmed in further clinical trials with larger patient 
numbers and longer follow-up times.
Guided Cardiopoiesis and Direct Reprogramming
MSCs
While the aforementioned studies all investigate CSCs/CPCs 
that are obtained from cardiac biopsies, other studies address the 
use of lineage-specified cardiopoietic cells. MSCs are one of the 
possible cell sources for guided cardiopoiesis. They have repeatedly 
been suggested as an immunoprivileged and therefore valuable 
clinical cell source for cardiac repair [8]. MSCs are multipotent 
stromal cells that are mainly characterized by their adherence 
properties, a distinct surface marker profile composed of markers 
such as CD29, CD44, CD105, CD73 and CD90, paracrine signal-
ing, and the ability to differentiate into the adipogenic, chondro-
genic and osteogenic lineage [22, 23]. A subset of MSCs can also 
differentiate into cardiomyocytes under specific conditions in vitro 
[22–24]. Due to their enormous expansion rate and immunomod-
ulatory properties, MSCs are considered as a potential candidate 
for both autologous and allogeneic stem cell therapy. Guided cardi-
opoiesis of autologous BMMSCs has been proposed as a next-gen-
eration approach for targeted cardiac repair [3, 5]. Supported by 
preclinical studies, the translation into distinct clinical settings, 
aiming to assess the therapeutic potential for patients suffering 
from MI or HF, was proven to be safe, feasible, and partially effi-
cient as shown by improved LVEF [25]. In the phase II Cardio-
poietic stem Cell therapy in heart failURE trial (C-CURE, 
NCT00810238), cardiopoietic stem cells were derived from 
BMMSCs that were treated with cardiogenic growth factors. These 
cells were injected endomyocardially into HF patients. Safety, feasi-
bility, and efficacy were assessed 6 months and 2 years after treat-
ment. The results were encouraging and showed an increase in 
LVEF [5, 26]. They lead to the two ongoing phase III Congestive 
Heart failure Cardiopoietic Regenerative Therapy trials (CHART-1 
and CHART-2, NCT01768702) [6, 27, 28]. Nevertheless, the dif-
ferentiation capacity of MSCs should be investigated in more 
detail. 
Embryonic Stem Cells (ESCs)
Although multipotent cells like MSCs possess a considerable 
potential for lineage specification, ESCs depict the gold standard 
for cardiomyocyte generation [13]. ESCs are blastocyst-derived 
cells that are pluripotent, meaning that they can differentiate into 
any cell type of the adult human body. ESC-derived cardiomyo-
cytes offer the possibility to directly contribute to heart contractil-
ity without any reprogramming-induced genomic alterations [23, 
29]. However, ESCs have not been considered for clinical trials for 
a long time due to several significant limitations, such as the pro-
pensity to form teratomas, potential immunological rejection after 
injection in vivo as well as substantial ethical concerns regarding 
the use of human ESCs [30, 31]. To limit potential teratoma forma-
tion, genetic selection of differentiated ESCs or the differentiation 
of ESCs into cardiomyocytes has been suggested for cardiac stem 
cell therapy [32–35]. In several preclinical studies entailing the 
transplantation of non-teratogenic human ESC-derived cardiac 
progenitors into rat and non-human primate models of myocardial 
infarction, Menasché et al. [36] have confirmed that these cells are 
effective in improving cardiac function. The procedure has yielded 
remarkably positive outcomes concerning cardiac differentiation 
as well as improvement in LV function. Moreover, it was found 
that epicardial delivery of ESC-derived cardiac progenitors embed-
ded in a fibrin patch is far more effective than multiple intramyo-
cardial injections with regard to cell engraftment and functional 
outcome. These data have paved the way for a translational phase I 
clinical trial with the goal to prove feasibility and safety in 6 pa-
tients. The world-first and ongoing Transplantation of Human 
Embryonic Stem Cell-derived Progenitors in Severe Heart Failure 
trial (ESCORT, NCT02057900) is a unique proof-of-concept study, 
which was initiated in 2013. Patients with ischemic HF epicardially 
receive human ESC-derived CD15+ Isl-1+ progenitors that are em-
bedded into a fibrin patch, in addition to coronary artery bypass 
graft surgery and/or a mitral valve procedure. The first case of one 
of the patients who has reached the 3-month follow-up time point 
showed that LVEF improved from 26 to 36%. No complications 
such as arrhythmias, tumor formation or immunosuppression-re-
lated adverse events could be observed. These data demonstrate the 
feasibility of transferring clinical-grade human ESC-derived pro-
genitor cells embedded in a fibrin patch to the diseased myocar-
dium and the relatively good tolerance of these cells. However, a 
more extensive follow-up as well as an increased number of pa-
tients will allow further documentation of safety and efficacy of 
human ESCs in cardiac regenerative medicine [37]. 
Induced Pluripotent Stem Cells (iPSCs)
iPSCs represent a possible solution to overcome the ethical and 
immunological issues raised by ESCs. Indeed, iPSCs recapitulate 
the properties of ESCs although they are derived from adult so-
matic cells. Originally, iPSCs were obtained by retroviral repro-
gramming with gene cocktails, but novel safer nonviral techniques 
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include the use of reprogramming proteins, small molecules, or 
miRNAs [12]. It has been shown that iPSCs can differentiate into 
cells of the three germ layers including cardiomyocytes [38]. 
Human iPSCs-derived cardiomyocyte sheets have been implanted 
in a porcine model of ischemic cardiomyopathy [39]. The cells 
could be detected up to 8 weeks after implantation, but the survival 
was low on the long term. No teratoma formation was observed, 
and the cardiac function was improved. Recently, human iPSCs 
have been differentiated into the three cardiac lineages (cardiomy-
ocytes, smooth muscle cells, and endothelial cells) and have been 
transplanted in a porcine model of MI [40]. Cell engraftment and 
improved cardiac function could be observed without the appear-
ance of ventricular arrhythmias. Reprogramming of fibroblasts 
into expandable induced CPCs and differentiation of pluripotent 
stem cells can provide an increased access to CPCs [41, 42]. De-
spite these positive preliminary results, important safety concerns 
such as rejection and teratoma formation still need to be thor-
oughly addressed before iPSCs can be used in a clinical setting.
Direct Reprogramming
Although the generation of cardiomyocytes from pluripotent 
stem cells bears great potential for cardiac regeneration, there are 
still severe concerns regarding their safety. In particular, the elimi-
nation of remaining pluripotent cells prior to implantation is a 
critical step, given that these cells could induce teratoma forma-
tion. The direct reprogramming of somatic cells into other cell 
types, such as cardiomyocytes, circumvents the pluripotent state 
and thus eliminates the issue of teratoma formation. The technique 
of traditional reprogramming using a cocktail of transcription fac-
tors inspired the direct reprogramming of one somatic cell type 
into another [43]. 
Over the last decade, it has been shown that murine fibroblasts 
can be transdifferentiated into functional cardiomyocyte-like cells 
using transduction with specific cocktails of transcription factors 
[44, 45]. Interestingly, the relatively low direct reprogramming ef-
ficiency of fibroblasts in vitro was improved when the transcrip-
tion factor cocktail was applied directly into the infarction zone in 
mice [12, 46]. The in vivo transduction of resident fibroblasts re-
sulted in improved cardiac function and decreased scar size [12]. 
Nevertheless, the cocktails successfully used in murine cells could 
not transform human fibroblasts into cardiomyocyte-like cells, 
whereas other compositions of defined transcription factors were 
able to do so [47]. De novo generation of cardiomyocytes would 
constitute an excellent tool for cardiac regeneration. However, the 
field of direct reprogramming is only in its infancy, and many is-
sues need to be overcome. Despite the persistent low efficiency, the 
cardiomyocyte-like cells obtained in vitro are still immature in 
their differentiation state and need to undergo additional matura-
tion steps to be considered adult cardiomyocytes. Once it can be 
shown that cardiomyocytes generated via direct reprogramming 
are functional in vitro, their safety and efficacy in preclinical HF 
models still needs to be evaluated [47]. An even more elegant solu-
tion for heart regeneration would be the direct in vivo conversion 
of resident cardiac fibroblasts into cardiomyocytes after cardiac in-
jury. This approach has been shown to be feasible and to improve 
cardiac function in a murine model. However, these investigations 
were performed using retroviral vectors, which bear the risk of 
non-target cell transduction as well as of non-controllable integra-
tion into the genome, resulting in insertional mutagenesis [43]. 
Given that cardiac direct reprogramming of murine and human 
fibroblasts needs different transcription factor cocktails [47], it is 
necessary to prove the in vivo direct reprogramming and safety 
also in large animal models to finally enable clinical translation in 
the long run.
Combination Therapies
Although intensive research is conducted to find the ideal cell 
type for cardiac stem cell therapy, it has been suggested that car-
diac regeneration could be achieved through the combination of 
several cell types with complementary properties.
Lately, the combination of MSCs and CSCs/CPCs has yielded 
interesting results. Based on the rationale that MSCs stimulate CSC 
proliferation [48], Williams and co-workers [49] hypothesized that 
combining MSCs and CSCs/CPCs has a greater effect on cardiac 
regeneration than delivering either cell type alone. Human MSCs 
and c-kit+ CSCs were isolated from bone marrow aspirates and en-
domyocardial biopsies, respectively, and were injected intramyo-
cardially either alone or in combination into an immunosup-
pressed swine model 14 days after MI. Hemodynamics measure-
ments, cMRI and histology showed that the combination therapy 
significantly enhanced scar size reduction, LV function and cell 
engraftment compared to the treatment with either cell type alone. 
The synergistic effect of MSCs and CSCs has also been shown re-
cently in a similar study in a non-immunosuppressed porcine 
model of chronic HF [50]. Autologous BMMSCs were delivered 
transendocardially either alone or in combination with autologous 
c-kit+ CSCs 3 months after ischemia/reperfusion injury. While 
scar size decreased and viable tissue increased in both cell-treated 
groups compared to placebo, cardiac function improved only in 
the combination group, as measured by LVEF, stroke volume, car-
diac output, regional diastolic strain rate and endothelial function 
3 months after treatment [50].
In the clinical setting, the CONCERT-HF trial (NCT02501811) 
is currently recruiting an estimated number of 144 patients with 
ischemic cardiomyopathy. This phase II randomized, placebo-con-
trolled study aims to assess the feasibility, safety, and efficacy of 
transendocardial injection of autologous BMMSCs and c-kit+ 
CSCs either in combination or alone.
Innovative tools have recently emerged in the field of combina-
torial cell therapy and include so-called CardioChimeras (CCs) 
and 3D-microtissues (3D-MTs) or spheroids. CCs were formed by 
ex vivo viral cell fusion between MSCs and CPCs and were allowed 
to undergo clonal expansion [51]. Two different clones with en-
hanced proliferation and survival properties (CC1 and CC2) were 
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chosen for further comparison with individual cell and combinato-
rial therapies in a mouse MI model. LV anterior wall thickness was 
improved by CCs 4 weeks after MI, but the improvement was only 
maintained by CC1 after 18 weeks. Functional improvements were 
also maintained by both the CCs and CPC+MSC groups up to 18 
weeks. Interestingly, infarct size was only decreased by CCs at 12 
weeks. Moreover, CCs showed increased persistence, engraftment 
and specific markers expression compared to other groups. Their 
paracrine function was finally shown by increased capillary density 
and preserved cardiomyocyte size in the infarcted region [51].
The aggregation of cells into 3D-MTs prior to transplantation 
might be an improvement for current cardiac regenerative strate-
gies [52, 53]. Indeed, 3D-MTs are thought to enhance cell retention 
and engraftment thanks to the production of extracellular matrix. 
Their more physiological 3D environment is supposed to recapitu-
late the stem cell niche. 3D-MTs can also serve as new tools for co-
culture of multiple cell types [54]. They can contain mixed cell 
types, be coated with a different cell type, or be fused to produce 
Janus spheroids [55]. Interestingly, 3D co-culture of murine cardi-
omyocytes with endothelial cells or MSCs could constitute a re-
markable model for the mechanisms of angiogenesis and vasculo-
genesis [56].
While therapies with MSCs and CSCs have proven to be safe 
and moderately efficient, the combination of these two cell types 
appears to enhance the individual effects of each cell type. This 
combinatorial approach is thus raising hope to achieve improved 
cardiac regeneration in future preclinical and clinical trials. Ingen-
ious tools such as CCs and 3D-MTs composed of different cell 
types might help to unveil new routes toward successful cardiac 
stem cell therapy.
Discussion
The heart is well known to have a limited capacity for self-re-
newal. Therefore, cell-based therapies have been repeatedly sug-
gested as a potential strategy for myocardial regeneration. While in 
initial preclinical and clinical studies, so-called unselected, first-
generation cell types have only led to moderate and heterogeneous 
therapeutic effects, there is a clear need for so-called next-genera-
tion stem cell therapies as well as combined approaches in order to 
enhance the regenerative potential of such regenerative therapies 
(fig.  1). Numerous cell populations have been evaluated in the 
translational setting presenting with a heterogeneous safety and ef-
ficacy profile. BMMSCs have proven to be safe and beneficial in 
preclinical as well as clinical settings [57]. CSCs/CPCs obtained 
from heart biopsies can be applied in a patient-specific manner, 
but their harvesting requires an invasive procedure, and their isola-
tion and culture methods need to be improved. Although ESCs 
face ethical concerns, they have recently shown to be safe and effi-
cient in preclinical and clinical studies [36, 37]. While iPSCs repre-
sent a possible solution to overcome the ethical concerns raised by 
ESCs, they face immunological issues and bear teratogenic poten-
tial. Cardiac lineage commitment of the aforementioned cell types 
has been suggested as an effective way to improve the function of 
the diseased myocardium. Novel approaches such as guided cardi-
opoiesis and direct reprogramming into cardiomyocytes create 
cardiac-committed cellular therapeutics, which can match the tar-
get organ and prompt regeneration without the need of invasive 
biopsies. Moreover, these approaches could reduce or even elimi-
nate immune rejection, and provide useful outcomes for creating 
not only a reasonable bench-to-bedside but also a reversed bed-to-
bench pathway, leading to the optimization of safety and efficacy 
issues of regenerative therapies [36].
A crucial issue in establishing more efficient cell-based thera-
pies for ischemic heart disease is to understand the mechanisms 
that affect myocardial performance and that are inherent to each 
cell type [23]. Electrical coupling, differentiation, and paracrine 
signaling represent the most desired mechanisms. Therefore, com-
bination therapies involving several cell types should be taken into 
consideration as these might induce synergistic and complemen-
tary effects on cardiac regeneration by combining different thera-
peutic mechanisms at a time. Also, depending on different cardiac 
pathologies, such as acute MI and chronic ischemic cardiomyopa-
thy, the combination of different cell types might be required to 
obtain efficient outcomes [50, 58], especially because ischemic 
heart disease does not only affect muscular structure and function 
but also nervous, vascular and extracellular matrix structures. CCs 
and 3D-MTs have recently emerged as combinatorial tools to 
mimic the physiological microenvironment of the target organ [51, 
Fig. 1. Evolution of first-generation, next-genera-
tion and combined stem cell-based approaches for 
cardiac regeneration (schematic overview with rep-
resentative cell types for BMMNCs, ESC-derived 
cardiomyocytes, CCs). BMMNCs = Bone marrow 
mononuclear cells; HPCs = hematopoietic stem 
cells; SMs = skeletal myoblasts; EPCs = endothelial 
progenitor cells; MSCs = mesenchymal stem cells; 
ESCs = embryonic stem cells; iPSCs = induced pluri-
potent stem cells; CSCs/CPCs = cardiac stem and 
progenitor cells; cpMSCs = cardiopoietic stem cells; 
CCs = cardiochimeras; MTs = 3D-microtissues.
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56]. Another approach that is still unexplored and worth to be in-
vestigated is the repeated stem cell administration to the diseased 
area. Furthermore, the systematic comparison between autologous 
and allogeneic cell sources provides new insights into putative al-
logeneic off-the-shelf cell therapy products in the future. Alloge-
neic approaches would be beneficial to reduce technical and logis-
tical challenges and accelerate the recovery process of the patients 
[59]. Standard operating procedures (SOPs) are needed for cell 
processing and expansion between cell harvesting and their 
implantation. 
Conclusion
Although the regenerative properties of the heart are known to 
be limited, stem cell therapy holds great promise for the treatment 
of ischemic heart disease. While several studies have demonstrated 
the safety and feasibility of various cell sources and delivery modes 
over more than a decade in different clinical settings, recent studies 
have started focusing more on the improvement of the efficacy of 
cell therapy. However, the precise mode of repair, such as differen-
tiation and paracrine signaling after cell transplantation, remains 
unclear. The first and most obvious obstacle is the identification of 
the optimal cell type for a successful translation into the clinical 
arena. Further issues such as the cell dose, delivery route, and tim-
ing remain to be solved, although it is suggested that higher cell 
numbers promote better outcomes [60]. Nevertheless, the appro-
priate dose depends most probably on the cell type, combinatorial 
products, donor age, and of course on the given cardiac pathology. 
Hence, ischemic heart disease might be treated with therapeutic 
cell products in the future, and patients might receive a unique and 
customized therapy according to their individual needs. However, 
the translational path leading to these outcomes is still long and 
requires GMP-compliant up-scaling and more valuable controlled 
trials.
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